PARP inhibitor Company PARP inhibition Details Olaparib (AZD2281) AstraZeneca PARP 1/2/3 Licensed in EU for maintenance BRCAm; ≥3rd line (FDA) in BRCAm. Phase III trials with tablet formulation – first…
Fig. 2.1 BRCA, DNA repair and the cell cycle (Foulkes and Shuen [9]). In response to DNA damage, BRCA1 mediates HR (depicted in the outer ring) and cell cycle regulation…
Fig. 10.1 Criteria for decision making When Should the Relapse Be Treated? In most of cases, CA 125 elevation is the first signal of recurrence; it can be observed some…
Items Possible responses (score) A Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties? 0 = severe decrease…
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_8 8. First-Line Systemic Therapy (Chemo/Antiangiogenics) Sandro Pignata1 and Sabrina Chiara Cecere1 (1) Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G…
NCT# Name Type – site Objective MRI NCT02243059 MILO Maastricht University Medical Center Magnetic resonance imaging for lymph node staging in ovarian cancer NCT02334371 Maastricht University Medical Center MR-PET for…
FIGO stage Intra-abdominal residual disease Radiological and clinically negative LN Positive lymph nodes >1 cm FIGO I–II 0 >0: stop doing surgery for ovarian cancer Yes Complete surgical staging −/−…
Author Year of publication Patients n Relapses n (%) FIGO stage IA FIGO stage IC Histological type Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Serous…
Author (year) N (Period recruitment /year) Timing Drug (mg/m2) Mortality PFS median months OS median months Cotte (2007) [39] 81 (14) M Cis (20) 2.5 % 19 28 Pavlov (2009)…
Study n % optimal primary surgery % optimal interval surgery PFS primary PFS interval OS primary OS interval EORTC [15] 319 0 45 % 13 months 18 months 20 months…
